Page last updated: 2024-10-31

mofezolac and Ileal Diseases

mofezolac has been researched along with Ileal Diseases in 1 studies

mofezolac: Cyclooxygenase 1 inhibitor; structure in first source; RN from Toxlit

Ileal Diseases: Pathological development in the ILEUM including the ILEOCECAL VALVE.

Research Excerpts

ExcerptRelevanceReference
" Toxic signs caused by N-22 administration, observed only in the 200 mg/kg group, were as follows: soiling around the mouth and/or nose, piloerection, anemia, diarrhea, emaciation and decreased spontaneous locomotor activity."1.28[Three-month oral subacute toxicity study of mofezolac (N-22) in rats]. ( Aoki, Y; Hashimoto, Y; Kiguchi, M; Kuwata, M; Okazaki, S; Shimpo, K; Takeuchi, M; Yamashita, K, 1990)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shimpo, K1
Takeuchi, M1
Okazaki, S1
Kiguchi, M1
Hashimoto, Y1
Aoki, Y1
Kuwata, M1
Yamashita, K1

Other Studies

1 other study available for mofezolac and Ileal Diseases

ArticleYear
[Three-month oral subacute toxicity study of mofezolac (N-22) in rats].
    The Journal of toxicological sciences, 1990, Volume: 15 Suppl 2

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Chemical Analysis; Dri

1990